Day: January 12, 2026

Operational Highlights DecemberOccupancy reached 71% in December, resulting in a full-year occupancy of 72% for 2025. Average Cabin Revenue (ACR) increased by 10% compared to December 2024, resulting in a 20% increase for the full year 2025 versus 2024. Total ticket revenue for December was 15% higher than December 2024. The total increase for 2025 versus 2024 was 22%.Booking Position 202651% of 2026 capacity is booked, about 10% ahead of the same time last year. We target 10–15% ACR growth across cabin categories for 2026, supporting continued revenue growth and EBITDA margin expansion.Booking Position 20278% of 2027 capacity is booked, about 4% points ahead of same time last year*The KPIs provided are sourced from the Company’s (unaudited) booking system. Consequently, there may be variations or minor discrepancies in...

A Media Snippet accompanying this announcement is available by clicking on this link. LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced it has renewed a multi-year agreement with Formula 1®, with Getty Images continuing to serve as Official Photographic Agency of Formula 1®. The multi-year partnership will see Getty Images’ award-winning motorsport photographers and editors continue to provide comprehensive coverage of all F1, F2, F3, F1 Academy and Porsche Supercup races. In 2025, Getty Images’ team criss-crossed the globe to deliver premium imagery of all F1 action throughout Formula 1®’s 75th anniversary year, working relentlessly across race weekends to capture unique perspectives from key moments on and off the track, including unique...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE NEWSWIRE) — ZYUS Life Sciences Corporation (the “Company“) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced that it has launched a brokered private placement of a minimum of 23,809,523 units of the Company (each a “Unit”) and up to a maximum of 25,396,825 Units, at a price of C$0.63 per Unit (the “Offering Price”), for minimum gross proceeds of C$15,000,000 and maximum gross proceeds of up to C$16,000,000 (the “LIFE Offering”). Each Unit will be comprised of one common share of the Company (each, a “Common Share”) and one-half (½) of one Common Share purchase...

SINGAPORE, Jan. 12, 2026 (GLOBE NEWSWIRE) — Sound Group Inc. (“Sound Group” or the “Company”) (NASDAQ: SOGP), a global AI-powered audio company, today issued a letter to shareholders from its Founder and CEO, Mr. Marco Lai. Dear Shareholders, As we step into 2026, Sound Group celebrates the sixth anniversary of its public listing. Over the past six years, we have navigated an environment defined by continuous change. Markets have fluctuated, industry landscapes have evolved, and new technologies have emerged. Yet some things have remained unchanged — our understanding of the value of voice, our judgement on strategic direction, and our commitment to thinking and acting for the long term. Since our founding in 2013, we have evolved from an audio content community to a real-time voice interaction platform, and now, to a company deeply...

Recognition by TechRadar Pro at CES 2026 underscores the strategic rationale behind Mixie’s strategic investment in HoloTwin’s AI-driven digital twin technology for enterprise and smart infrastructure operations DENVER, Jan. 12, 2026 (GLOBE NEWSWIRE) — Mixie Technologies, Inc. (OTC: PHCG), formerly known as Pure Harvest Corporate Group, Inc. (“Mixie”, “Mixie Technologies”, or the “Company”), today announced that HoloTwin LLC (“HoloTwin”) has been named a winner of the prestigious TechRadar Pro CES Picks Award 2026 in the category of Enterprise and Smart Infrastructure Innovation. The TechRadar CES Picks Award follows Mixie’s previously disclosed acquisition of a minority ownership interest in HoloTwin and reflects the Company’s strategy of investing in scalable, AI-enabled software platforms that address real operational challenges...

DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA”) custodian by number of accounts and leading provider of complimentary consumer-directed benefits (“CDBs”), today announced its initial outlook for its fiscal year ending January 31, 2027 and reaffirmed previously provided guidance for its fiscal year ending January 31, 2026. For the fiscal year ending January 31, 2027, management expects revenues in the range of $1.38 billion to $1.41 billion with Adjusted EBITDA margin of 43.8% to 44.3% and a yield on HSA Cash of approximately 3.75%. “Today, we issued our initial fiscal 2027 outlook, reflecting the progress we’ve made strengthening HealthEquity’s foundation and building momentum as a scaled platform,”...

Experienced medical executive advances to permanent role following successful leadership as Interim CMO SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has confirmed the promotion of Mark Rubinstein, M.D., from Interim Chief Medical Officer to Chief Medical Officer (CMO). Since Dr. Rubinstein began his tenure as Interim CMO in September 2025, the company has achieved significant clinical and regulatory milestones, and he co-authored the recent paper in Thorax of data demonstrating cytisinicline’s potential efficacy and tolerability for smoking cessation in individuals...

Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and financial outcomes SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Counterpart Health, Inc. (“Counterpart” or the “Company”), a leading AI-powered physician-enablement platform and subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), today released key 2025 highlights. The past year was defined by continued publication of research demonstrating the platform’s impact on chronic disease management, meaningful product expansion, and the scaled adoption of Counterpart Assistant (CA) by hundreds of live third-party customer clinicians across diverse practice settings. Clinical Quality and Financial Performance Outcomes Data released in 2025 highlights the scale...